Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib
Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib have?
Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib has 3 citations in the OpenAlex counts ScholarIQ stores.
When was Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib published?
Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib has 2024 year in the ScholarIQ index.
What is the open-access status of Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib?
Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib has gold oa status in the ScholarIQ index.
What is the DOI of Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib?
The DOI for Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib is on the source record.
What is the PMID of Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib?
The PMID for Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib is on the source record.
What is the OpenAlex record for Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib?
The OpenAlex for Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with<i>EGFR</i>-mutated non-small cell lung cancer treated with afatinib is on the source record.